Crossref
Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist
Clinical Nephrology · 2025
DOI: 10.5414/cn111488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nephrology, 2025. Verfasst von Rose Mary Attieh und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hyperphosphatemia.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
HyperphosphatemiaHumansMaleFemaleAgedMiddle AgedReceptors, Fibroblast Growth FactorIncidenceAntineoplastic AgentsPyrazolesRetrospective StudiesAged, 80 and overProtein Kinase InhibitorsQuinoxalines
Substanzen
Receptors, Fibroblast Growth FactorAntineoplastic AgentserdafitinibPyrazolesProtein Kinase InhibitorsQuinoxalines
Zitieren
APA
Attieh, R. M., Upadrista, P., Levy, A. T., & Jhaveri, K. D. (2025). Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist. Clinical Nephrology. https://doi.org/10.5414/cn111488
Vancouver
Attieh RM, Upadrista P, Levy AT, Jhaveri KD. Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist. Clinical Nephrology. 2025. doi:10.5414/cn111488
BibTeX
@article{Attieh2025,
author = {Attieh, Rose Mary and Upadrista, Pratap and Levy, Anna T and Jhaveri, Kenar D},
title = {Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist},
journal = {Clinical Nephrology},
year = {2025},
doi = {10.5414/cn111488}
}
EUVIMED